Dr. Andrea Apolo

But that may be the way that we treat patients. We treat them systemically with therapy and hopefully not remove their bladder. So in a way that failure is actually a success for patients.

But that may be the way that we treat patients. We treat them systemically with therapy and hopefully not remove their bladder. So in a way that failure is actually a success for patients.

But that may be the way that we treat patients. We treat them systemically with therapy and hopefully not remove their bladder. So in a way that failure is actually a success for patients.

Yeah, no, I completely agree. We need to learn from those patients. Yeah.

Yeah, no, I completely agree. We need to learn from those patients. Yeah.

Yeah, no, I completely agree. We need to learn from those patients. Yeah.

Well, just that I think time will tell in terms of the rest of the outcomes of that trial and their other trials. Also, that we're awaiting their data that include platinum-based, cisplatinum-based chemotherapy in combination with with a checkpoint inhibitor, including the Energize study with nivolumab. And we also have the Keynote 866 study with pembrolizumab.

Well, just that I think time will tell in terms of the rest of the outcomes of that trial and their other trials. Also, that we're awaiting their data that include platinum-based, cisplatinum-based chemotherapy in combination with with a checkpoint inhibitor, including the Energize study with nivolumab. And we also have the Keynote 866 study with pembrolizumab.

Well, just that I think time will tell in terms of the rest of the outcomes of that trial and their other trials. Also, that we're awaiting their data that include platinum-based, cisplatinum-based chemotherapy in combination with with a checkpoint inhibitor, including the Energize study with nivolumab. And we also have the Keynote 866 study with pembrolizumab.

So there are additional trials that had this similar approach where they gave neoadjuvant cisplatinase-based chemotherapy with a checkpoint, and then there was an adjuvant component. So I think reading, I think the outcome of those trials will be super important. But for now, I mean, I think that we have to consider this a new standard of care. I mean, patients did so well.

So there are additional trials that had this similar approach where they gave neoadjuvant cisplatinase-based chemotherapy with a checkpoint, and then there was an adjuvant component. So I think reading, I think the outcome of those trials will be super important. But for now, I mean, I think that we have to consider this a new standard of care. I mean, patients did so well.

So there are additional trials that had this similar approach where they gave neoadjuvant cisplatinase-based chemotherapy with a checkpoint, and then there was an adjuvant component. So I think reading, I think the outcome of those trials will be super important. But for now, I mean, I think that we have to consider this a new standard of care. I mean, patients did so well.

They had an improvement in event-free survival, but they also had an improvement in overall survival. And that's so important for our patients because We've struggled to show an overall survival benefit in the perioperative setting. So we can be really critical about this trial, the way that they over-treated patients, but there was an overall survival benefit.

They had an improvement in event-free survival, but they also had an improvement in overall survival. And that's so important for our patients because We've struggled to show an overall survival benefit in the perioperative setting. So we can be really critical about this trial, the way that they over-treated patients, but there was an overall survival benefit.

They had an improvement in event-free survival, but they also had an improvement in overall survival. And that's so important for our patients because We've struggled to show an overall survival benefit in the perioperative setting. So we can be really critical about this trial, the way that they over-treated patients, but there was an overall survival benefit.

So I think, you know, we should consider including Dervalumab now in the neoadjuvant setting and in the adjuvant setting.

So I think, you know, we should consider including Dervalumab now in the neoadjuvant setting and in the adjuvant setting.

So I think, you know, we should consider including Dervalumab now in the neoadjuvant setting and in the adjuvant setting.

I think we're learning. I think that's a great concern to have. In this study so far, they did not report any issues with surgical outcomes or even post-surgical outcomes.

I think we're learning. I think that's a great concern to have. In this study so far, they did not report any issues with surgical outcomes or even post-surgical outcomes.